Evaluation of the therapeutic efficacy of sequential therapy involving percutaneous microwave ablation in combination with 131I-hypericin using the VX2 rabbit breast solid tumor model

• Published in: PloS one Vol. 10; no. 3; p. e0120303
• Main Authors: Zhu, Miao, Lin, Xiao-An, Zha, Xiao-Ming, Zhou, Wen-Bin, Xia, Tian-Song, Wang, Shui
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 2015; Public Library of Science (PLoS)
• Subjects: Ablation; Ablation Techniques; Abnormalities; Animals; Antineoplastic Agents - adverse effects; Antineoplastic Agents - pharmacokinetics; Antineoplastic Agents - therapeutic use; Autoradiography; Breast; Breast cancer; Breast carcinoma; Cancer therapies; Carcinoma - drug therapy; Carcinoma - surgery; Computed tomography; Drug Evaluation, Preclinical; Emission analysis; Female; Gangrene; Hospitals; Hypericin; Intravenous administration; Laboratory animals; Liver; Lung cancer; Lungs; Mammary Neoplasms, Experimental - drug therapy; Mammary Neoplasms, Experimental - surgery; Mastectomy; Medical research; Metastases; Microwave ablation; Microwaves - adverse effects; Microwaves - therapeutic use; Perylene - adverse effects; Perylene - analogs & derivatives; Perylene - pharmacokinetics; Perylene - therapeutic use; Positron emission; Positron emission tomography; Rabbits; Radiation therapy; Radiosurgery; Renal function; Scintigraphy; Side effects; Solid tumors; Surgery; Survival; Therapy; Tissue Distribution; Tomography; Tumors; Ultrasonic imaging; China
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0120303

Combination of percutaneous microwave ablation (PMWA) and intravenous injection of 131I-hypericin(IIIH) may bear potential as a mini-invasive treatment for tumor. The objective of this study was to assess the effect of PMWA and IIIH in breast tumor growth. Ten New Zealand White rabbits bearing VX2 breast carcinomas were randomly divided into two groups (each 5 examples) and processed using PMWA followed by IIIH and IIIH alone. The IIIH activity was evaluated using planar scintigraphy, autoradiography and biodistribution analysis. The maximum effective safe dose of IIIH was found through 48 rabbits with VX2 breast tumor, which were randomized into six groups (n=8 per group). Subsequently, a further 75 rabbits bearing VX2 breast solid tumors were randomly divided into five groups (each 15 examples) and treated as follows: A, no treatment group; B, PMWA alone; C, IIIH alone; D, PMWA+IIIH×1 (at 8 h post-PMWA); and E, PMWA+IIIH×2 (at 8 h and at 8 days post-PMWA). The therapeutic effect was assessed by measurement of tumor size and performation of positron emission tomography/computed tomograph (PET/CT) scans, liver and renal function tests and Kaplan-Meier survival analysis. The planar scintigraphy findings suggested a significant uptake of 131I in necrotic tumor tissue. The autoradiography gray scales indicated higher selective uptake of IIIH by necrotic tissue, with significant differences between the groups with and those without necrotic tumor tissue (P<0.05). The maximum effective safe dose of IIIH was 1 mCi/kg. The PET/CT scans and tumor size measurement suggested improvements in treatment groups at all time points (P<0.01). Significant differences were detected among Groups A, B, D and E (P<0.05). Lower levels of lung metastasis were detected in Groups D and E (P<0.05). There were no abnormalities in liver and renal functions tests or other reported side effects. IIIH exhibited selective uptake by necrotic tumor tissue. Sequential therapy involving PMWA+IIIH was successfully inhibiting tumor growth and prolonging survival.